company background image
ABBV

AbbVie NYSE:ABBV Stock Report

Last Price

US$142.60

Market Cap

US$252.1b

7D

3.3%

1Y

22.4%

Updated

14 Aug, 2022

Data

Company Financials +
ABBV fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance5/6
Financial Health3/6
Dividends6/6

ABBV Stock Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.

AbbVie Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AbbVie
Historical stock prices
Current Share PriceUS$142.60
52 Week HighUS$175.91
52 Week LowUS$105.56
Beta0.68
1 Month Change-7.17%
3 Month Change-8.28%
1 Year Change22.42%
3 Year Change121.32%
5 Year Change103.83%
Change since IPO307.43%

Recent News & Updates

Aug 03

AbbVie gets FDA approval for JUVÉDERM to improve jawline definition

The U.S. Food and Drug Administration (FDA) approved AbbVie's (NYSE:ABBV) JUVÉDERM Volux XC for improving jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition. "JUVÉDERM VOLUX XC complements our existing product line to provide even more structure, cohesivity and lift capacity to create an improved jawline that appears more defined in real life and on camera," said Carrie Strom, president, Global Allergan Aesthetics and senior vice president, AbbVie.

Jul 27

AbbVie unit Allergan in $2B opioid settlement with state, local governments - Bloomberg

Allergan, a subsidiary of AbbVie (NYSE:ABBV), has agreed to a $2B settlement with state and local governments that would end thousands of lawsuits related to its opioid Kadian (morphine sulfate), Bloomberg reported. More than 3K lawsuits would be settled under the arrangement. Details are still be working out with a federal court in Cleveland. In December, Allergan reached a $200M opioid settlement with New York State. Teva Pharmaceutical (TEVA) on Tuesday announced a $4.35B settlement.

Shareholder Returns

ABBVUS BiotechsUS Market
7D3.3%1.2%3.2%
1Y22.4%-21.7%-10.2%

Return vs Industry: ABBV exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: ABBV exceeded the US Market which returned -10.2% over the past year.

Price Volatility

Is ABBV's price volatile compared to industry and market?
ABBV volatility
ABBV Average Weekly Movement3.1%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: ABBV is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: ABBV's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201250,000Rick Gonzalezhttps://www.abbvie.com

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic.

AbbVie Fundamentals Summary

How do AbbVie's earnings and revenue compare to its market cap?
ABBV fundamental statistics
Market CapUS$252.13b
Earnings (TTM)US$12.57b
Revenue (TTM)US$57.35b

20.1x

P/E Ratio

4.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABBV income statement (TTM)
RevenueUS$57.35b
Cost of RevenueUS$16.79b
Gross ProfitUS$40.56b
Other ExpensesUS$27.99b
EarningsUS$12.57b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)7.11
Gross Margin70.72%
Net Profit Margin21.92%
Debt/Equity Ratio498.3%

How did ABBV perform over the long term?

See historical performance and comparison

Dividends

4.0%

Current Dividend Yield

78%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is ABBV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABBV?

Other financial metrics that can be useful for relative valuation.

ABBV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.5x
Enterprise Value/EBITDA11.6x
PEG Ratio59.5x

Price to Earnings Ratio vs Peers

How does ABBV's PE Ratio compare to its peers?

ABBV PE Ratio vs Peers
The above table shows the PE ratio for ABBV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average18.7x
AMGN Amgen
20.2x10.0%US$132.9b
VRTX Vertex Pharmaceuticals
23.6x9.3%US$75.5b
GILD Gilead Sciences
19.1x11.3%US$78.9b
REGN Regeneron Pharmaceuticals
11.8x-1.5%US$67.2b
ABBV AbbVie
20.1x0.3%US$252.1b

Price-To-Earnings vs Peers: ABBV is expensive based on its Price-To-Earnings Ratio (20.1x) compared to the peer average (18.7x).


Price to Earnings Ratio vs Industry

How does ABBV's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Earnings vs Industry: ABBV is expensive based on its Price-To-Earnings Ratio (20.1x) compared to the US Biotechs industry average (15.9x)


Price to Earnings Ratio vs Fair Ratio

What is ABBV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABBV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.1x
Fair PE Ratio25.9x

Price-To-Earnings vs Fair Ratio: ABBV is good value based on its Price-To-Earnings Ratio (20.1x) compared to the estimated Fair Price-To-Earnings Ratio (25.9x).


Share Price vs Fair Value

What is the Fair Price of ABBV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ABBV ($142.6) is trading below our estimate of fair value ($353.68)

Significantly Below Fair Value: ABBV is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Future Growth

How is AbbVie forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


0.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABBV's forecast earnings growth (0.3% per year) is below the savings rate (1.9%).

Earnings vs Market: ABBV's earnings (0.3% per year) are forecast to grow slower than the US market (14.5% per year).

High Growth Earnings: ABBV's earnings are forecast to grow, but not significantly.

Revenue vs Market: ABBV's revenue (0.5% per year) is forecast to grow slower than the US market (7.9% per year).

High Growth Revenue: ABBV's revenue (0.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ABBV's Return on Equity is forecast to be very high in 3 years time (90.1%).


Discover growth companies

Past Performance

How has AbbVie performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


12.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ABBV has high quality earnings.

Growing Profit Margin: ABBV's current net profit margins (21.9%) are higher than last year (12.3%).


Past Earnings Growth Analysis

Earnings Trend: ABBV's earnings have grown by 12.6% per year over the past 5 years.

Accelerating Growth: ABBV's earnings growth over the past year (90.6%) exceeds its 5-year average (12.6% per year).

Earnings vs Industry: ABBV earnings growth over the past year (90.6%) exceeded the Biotechs industry 24.5%.


Return on Equity

High ROE: Whilst ABBV's Return on Equity (86.1%) is outstanding, this metric is skewed due to their high level of debt.


Discover strong past performing companies

Financial Health

How is AbbVie's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ABBV's short term assets ($29.1B) do not cover its short term liabilities ($34.5B).

Long Term Liabilities: ABBV's short term assets ($29.1B) do not cover its long term liabilities ($94.0B).


Debt to Equity History and Analysis

Debt Level: ABBV's net debt to equity ratio (430.5%) is considered high.

Reducing Debt: ABBV's debt to equity ratio has reduced from 624.1% to 498.3% over the past 5 years.

Debt Coverage: ABBV's debt is well covered by operating cash flow (31.3%).

Interest Coverage: ABBV's interest payments on its debt are well covered by EBIT (8.5x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is AbbVie current dividend yield, its reliability and sustainability?

Dividend Score

6/6

Dividend Score 6/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


3.96%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: ABBV's dividend (3.96%) is higher than the bottom 25% of dividend payers in the US market (1.47%).

High Dividend: ABBV's dividend (3.96%) is in the top 25% of dividend payers in the US market (3.95%)


Stability and Growth of Payments

Stable Dividend: ABBV's dividends per share have been stable in the past 10 years.

Growing Dividend: ABBV's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: At its current payout ratio (77.9%), ABBV's payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (44.9%), ABBV's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Rick Gonzalez (68 yo)

9.58yrs

Tenure

US$23,912,154

Compensation

Mr. Richard A. Gonzalez, also known as Rick, serves as the Chairman of AbbVie Inc. and has been its Chief Executive Officer at AbbVie Inc. since 2013. Mr. Gonzalez served as an Executive Vice President of...


CEO Compensation Analysis

Compensation vs Market: Rick's total compensation ($USD23.91M) is above average for companies of similar size in the US market ($USD12.88M).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ABBV's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: ABBV's board of directors are considered experienced (9.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AbbVie Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: AbbVie Inc.
  • Ticker: ABBV
  • Exchange: NYSE
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$252.131b
  • Shares outstanding: 1.77b
  • Website: https://www.abbvie.com

Number of Employees


Location

  • AbbVie Inc.
  • 1 North Waukegan Road
  • North Chicago
  • Illinois
  • 60064-6400
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/14 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.